Satellite Evening Meeting:
Janssen Oncology Satellite Symposium
Integration of new Agents into the Management of Castration Resistant Prostate Cancer
Professor Oliver Sartor Tulane University School of Medicine, USA
Dr. Sartor is a graduate of Tulane Medical School (1982) and was elected President of the AOA Honor Society. After completing Residency in Internal Medicine at Tulane in 1986, he served as a Fellow in the Medical Oncology Branch of the National Cancer Institute in Bethesda, Maryland. From 1990-1993 he served as a Senior Investigator at the National Cancer Institute in the Clinical Pharmacology Branch where he began to focus on novel therapeutics and clinical trials for advanced prostate cancer patients. He was the Director of the Stanley S. Scott Cancer Center, and served as Chief of the Hematology/Oncology Section at the Louisiana State University (LSU) Health Sciences Center in New Orleans from 1998-2006.
After Hurricane Katrina, he departed New Orleans to join the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Harvard Medical School in Boston. He returned to Tulane Medical School in 2008 as the Piltz Professor of Cancer Research with a joint appointment in the Departments of Medicine and Urology. He has now been named the LaBorde Professor for Cancer Research. In 2010 he was appointed as the Medical Director of the Tulane Cancer Center.Dr. Sartor’s research and clinical interests have focused broadly on prostate cancer over the past 20 years.
His publications range from the genetic studies on prostate cancer, to studies of ethnic populations, to clinical trials involving novel agents. Among other duties, he is past-Chairman of the Integration Panel for the Department of Defense’s Congressionally Directed Medical Research Program in Prostate Cancer and the Medical Oncology Chairman of the GU Oncology Committee at the Radiation Therapy Oncology Group (RTOG). He has lead a number of large international trials in prostate cancer, including those leading to the FDA approval of samarium-153 EDTMP and cabazitaxel.
Date: Wednesday 19 August 2015
Time: 17:30 – 18:30
(refreshments from 17:15)
Location: Cairns Convention Centre
Speaker: Professor Oliver Sartor
Chair: Dr Daniel Moon
Satellite Breakfast Meeting:
Individualising Treatment Options for Metastatic Castrate-Resistant Prostate Cancer 
Proudly sponsored by Astellas
Thursday 20 August 2015
Time: 0645 – 0745
Venue: Cairns Convention Centre – Meeting Room 8
|
06:45 – 06:50 |
Opening Chairperson: A/Prof Henry Woo (Urologist) |
|
06:50 – 07:20 |
Key note presentation Prof Howard Scher |
|
07:20 – 07:40 |
Case Study Panel Discussion Facilitator: A/Prof Henry Woo Panelists: Prof Howard Scher, A/Prof Scott Williams (Radiation Oncologist), A/Prof Nathan Lawrentschuk, (Urologist) A/Prof Lisa Horvarth (Oncologist) |
|
07:40 – 07:45 |
Summary & Closing Chairperson: A/Prof Henry Woo |